A cost effectiveness and capacity analysis for the introduction of universal rotavirus vaccination in Kenya : comparison between Rotarix and RotaTeq vaccines
van Hoek, Albert Jan, Ngama, Mwanajuma, Ismail, Amina, Chuma, Jane, Cheburet, Samuel, Mutonga, David, Kamau, Tatu and Nokes, D. James. (2012) A cost effectiveness and capacity analysis for the introduction of universal rotavirus vaccination in Kenya : comparison between Rotarix and RotaTeq vaccines. PLoS One, Vol.7 (No.10). e47511. ISSN 1932-6203
WRAP_Nokes_Cost_effectiveness_capacity.pdf - Published Version
Available under License Creative Commons Attribution.
Download (433Kb) | Preview
Official URL: http://dx.doi.org/10.1371/journal.pone.0047511
Diarrhoea is an important cause of death in the developing world, and rotavirus is the single most important cause of diarrhoea associated mortality. Two vaccines (Rotarix and RotaTeq) are available to prevent rotavirus disease. This analysis was undertaken to aid the decision in Kenya as to which vaccine to choose when introducing rotavirus vaccination.
Cost-effectiveness modelling, using national and sentinel surveillance data, and an impact assessment on the cold chain.
The median estimated incidence of rotavirus disease in Kenya was 3015 outpatient visits, 279 hospitalisations and 65 deaths per 100,000 children under five years of age per year. Cumulated over the first five years of life vaccination was predicted to prevent 34% of the outpatient visits, 31% of the hospitalizations and 42% of the deaths. The estimated prevented costs accumulated over five years totalled US$1,782,761 (direct and indirect costs) with an associated 48,585 DALYs. From a societal perspective Rotarix had a cost-effectiveness ratio of US$142 per DALY (US$5 for the full course of two doses) and RotaTeq US$288 per DALY ($10.5 for the full course of three doses). RotaTeq will have a bigger impact on the cold chain compared to Rotarix.
Vaccination against rotavirus disease is cost-effective for Kenya irrespective of the vaccine. Of the two vaccines Rotarix was the preferred choice due to a better cost-effectiveness ratio, the presence of a vaccine vial monitor, the requirement of fewer doses and less storage space, and proven thermo-stability.
|Item Type:||Journal Article|
|Subjects:||R Medicine > RA Public aspects of medicine > RA0421 Public health. Hygiene. Preventive Medicine|
|Divisions:||Faculty of Science > Life Sciences (2010- )|
|Library of Congress Subject Headings (LCSH):||Rotavirus infections -- Vaccination -- Cost effectiveness|
|Journal or Publication Title:||PLoS One|
|Publisher:||Public Library of Science|
|Official Date:||24 October 2012|
|Access rights to Published version:||Restricted or Subscription Access|
1. World Health Organisation (2009) Rotavirus vaccines: an update. Weekly
Actions (login required)